Natera Appoints New Director to Board

TL;DR

Natera adds Dr. Paul J. Hastings to its board.

AI Summary

Natera, Inc. announced on December 2, 2024, a change in its board of directors. Specifically, Dr. Paul J. Hastings has been appointed as a new director, effective immediately. This appointment is part of the company's ongoing governance and strategic planning.

Why It Matters

Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future decision-making.

Risk Assessment

Risk Level: low — The filing reports a routine board appointment, which typically carries low immediate risk.

Key Players & Entities

• Natera, Inc. (company) — Registrant
• Dr. Paul J. Hastings (person) — Newly appointed director
• December 2, 2024 (date) — Effective date of appointment

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share NTRA Nasdaq Stock Market

Filing Documents

• tm2430337d1_8k.htm (8-K) — 33KB
• 0001104659-24-126348.txt ( ) — 204KB
• ntra-20241202.xsd (EX-101.SCH) — 3KB
• ntra-20241202_lab.xml (EX-101.LAB) — 33KB
• ntra-20241202_pre.xml (EX-101.PRE) — 22KB
• tm2430337d1_8k_htm.xml (XML) — 4KB

02

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 2, 2024, Natera, Inc. (the "Company") entered into an Amended and Restated Employment Agreement (the "Agreement") with Matthew Rabinowitz, Ph.D., the Executive Chairman and Co-Founder of the Company, prior to the expiration of Dr. Rabinowitz's prior employment agreement. The Agreement, which has an effective date of November 1, 2024 (the "Effective Date"), amends and restates the Amended Employment Agreement previously entered into by the parties on June 7, 2007, as amended on May 9, 2021 and April 19, 2023. Continued Employment The Agreement provides that Dr. Rabinowitz will continue to serve as the Company's Executive Chairman on an at-will basis, and will receive an annual base salary equal to 50% of the annual base salary of the Company's Chief Executive Officer ("CEO"). He is also eligible to receive an annual cash bonus equal to 85% of his base salary based on the achievement of performance goals established and assessed by the Company's Board of Directors (the "Board") or its Compensation Committee. Dr. Rabinowitz will also be entitled to receive annual long-term equity awards during his continued service. Subject to the approval of the Board or the Compensation Committee, Dr. Rabinowitz will receive annual equity award(s) with a dollar value equal to 80% of the dollar value of the annual equity award(s) granted to the CEO for each fiscal year, in either case allocated among time-based and performance-based vesting conditions in the same proportions as the CEO's equity award(s). The value and number of shares underlying the equity award(s) granted will be calculated in accordance with the Company's equity grant policies and procedures. The equity awards will be made pursuant to, and subject to the terms and conditions of, the Company's 2015 Equity Incentive Plan. Severance Terms If

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Natera, Inc. By: /s/ Michael Brophy Michael Brophy Chief Financial Officer (Principal Financial and Accounting Officer) Dated: December 6, 2024

View Full Filing

View this 8-K filing on SEC EDGAR